No Data
No Data
Express News | Reported Earlier, Innovent's Phase 3 DREAMS-2 Trial Shows Mazdutide's Superiority Over Dulaglutide In Chinese Type 2 Diabetes Patients At EASD 2024
Head-to-head superiority to high-dose liraglutide, the phase III clinical study results of marserlin peptide for diabetes, DREAMS-2, were orally reported at EASD.
San Francisco, USA, and Suzhou, China, September 12, 2024 / PRNewswire / - Innovent Biologics Group (Hong Kong Stock Exchange: 01801), a biopharmaceutical company dedicated to the research, development, production, and sales of innovative drugs in major disease areas such as oncology, autoimmune, metabolism, cardiovascular, and ophthalmology, announced today that Marstedinide (research code: IBI362), a dual GLP-1R/GCGR agonist, for the treatment of type 2 diabetes, has initiated its Phase III clinical trial (DREAMS-2) in Chinese subjects.
Reported Earlier, Innovent Presents Update On Dupert (Fulzerasib) For KRAS G12C-Mutated NSCLC At 2024 World Conference On Lung Cancer
Express News | Reported Earlier, Innovent Receives FDA Fast Track Designation For IBI363, A PD-1/IL-2α Bispecific Antibody, As Monotherapy For Advanced Melanoma
The clinical research data of Mashido peptide will be reported at the 60th European Association for the Study of Diabetes (EASD) Annual Meeting.
On September 2, 2024, in San Francisco, USA, and Suzhou, China / PRNewswire / - Innovent Biologics Group (Hong Kong Stock Exchange stock code: 01801), a biopharmaceutical company dedicated to the research, development, production, and sales of innovative drugs in the field of major diseases such as tumors, autoimmune diseases, metabolism, cardiovascular diseases, and ophthalmology, announced that multiple clinical research data of MSIP-1 will be orally presented at the 60th Annual Meeting of the European Association for the Study of Diabetes (EASD), including the latest data from the Phase III clinical research DREAMS-2 for type 2 diabetes registration.
Innovent Bio will announce updated clinical data for multiple innovative pipeline products, including IBI363 (PD-1/IL-2α-bias), at the WCLC and ESMO 2024 conferences.
Innovent Bio (stock code: 01801) announced today that it will release nearly 20 clinical data, including 6 oral presentations, at the 25th World Conference on Lung Cancer (WCLC) and the 2024 European Society for Medical Oncology (ESMO) Annual Meeting. The WCLC conference will be held from September 7th to 10th, 2024 in San Francisco, USA and Suzhou, China.
No Data
No Data